1. HTA in Germany: very special and specific

   • Wolfgang Greiner
   • J.-Matthias Graf von der Schulenburg

   Editorial 20 January 2010 Pages: 1 - 3

2. On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected

   • Bengt Liljas

   Original Paper 03 March 2009 Pages: 5 - 13

3. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach

   • Jan Steffen Jürgensen
   • Wolfgang Arns
   • Bastian Haß

   Original Paper 19 March 2009 Pages: 15 - 25

   

4. Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study

   • Feng Xie
   • Ngai-Nung Lo
   • Hin-Peng Lee

   Original Paper 10 May 2009 Pages: 27 - 34

   

5. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective

   • Montserrat Vera-Llonch
   • Ellen Dukes
   • Gerry Oster

   Original Paper Open access 09 June 2009 Pages: 35 - 44

   

6. The added value of thorough economic evaluation of telemedicine networks

   • Myriam Le Goff-Pronost
   • Claude Sicotte

   Original Paper 27 June 2009 Pages: 45 - 55

7. An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?

   • Rachel A. Elliott
   • Helen L. A. Weatherly
   • Mark J. Sculpher

   Original Paper 08 August 2009 Pages: 57 - 66

   

8. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis

   • Yogesh Suresh Punekar
   • Neil Hawkins

   Original Paper 21 October 2009 Pages: 67 - 76

   

9. Health costs in patients treated for depression, in patients with depressive symptoms treated for another chronic disorder, and in non-depressed patients: a two-year prospective cohort study in anthroposophic outpatient settings

   • Harald J. Hamre
   • Claudia M. Witt
   • Helmut Kiene

   Original Paper Open access 13 November 2009 Pages: 77 - 94

   

10. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure

    • Sonja Merkesdal
    • Timm Kirchhoff
    • Andrea Rubbert-Roth

    Original Paper 05 December 2009 Pages: 95 - 104

    

11. Cost effectiveness of palivizumab in Spain: an analysis using observational data

    • Mark J. Nuijten
    • Wolfgang Wittenberg

    Original Paper Open access 05 December 2009 Pages: 105 - 115